Irinotecan in Treating Patients With Recurrent Malignant Glioma

Completed · Phase 1/Phase 2

Conditions studied: Brain and Central Nervous System Tumors

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of irinotecan in treating patients with recurrent malignant glioma.

Key facts

Study ID

NCT00003301

Run by

New Approaches to Brain Tumor Therapy Consortium

Starts

1998-07-01

Expected to finish

2004-04-01

Last updated by the study team

2013-06-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Alabama Comprehensive Cancer Center — Birmingham, Alabama, United States
• H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States
• Emory University Hospital - Atlanta — Atlanta, Georgia, United States
• Johns Hopkins Oncology Center — Baltimore, Maryland, United States
• Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States
• Henry Ford Hospital — Detroit, Michigan, United States
• Comprehensive Cancer Center of Wake Forest University Baptist Medical Center — Winston-Salem, North Carolina, United States
• University of Pennsylvania Cancer Center — Philadelphia, Pennsylvania, United States
• University of Texas Health Science Center at San Antonio — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.